help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stern, N.
Right arrow Articles by Nadler, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stern, N.
Right arrow Articles by Nadler, J. L.

Endocrinology, Vol 125, 3090-3095, Copyright © 1989 by Endocrine Society


ARTICLES

Selective inhibition of angiotensin-II-mediated aldosterone secretion by 5-hydroxyeicosatetraenoic acid

N Stern, R Natarajan, ML Tuck, E Laird and JL Nadler
Sepulveda Veterans Administration Medical Center, California 91343.

We have previously demonstrated that the 12-lipoxygenase (12-LO) pathway plays a key role in angiotensin-II (AII)-dependent aldosterone production. In the present study we examined the role of the 5LO pathway on AII-induced aldosterone secretion in rat glomerulosa cells in vitro. The 5LO product 5-hydroxyeicosatetraenoic acid (5HETE) and its unstable precursor 5-hydroxyperoxyeicosatetraenoic acid did not significantly alter basal aldosterone secretion in concentrations from 10(-9)-10(-7) M. In contrast, 5HETE reduced peak AII-induced aldosterone production from 59.1 +/- 9.0 to 37.96 +/- 7.2 ng/10(6) cells (P less than 0.01). This was accompanied by inhibition of the AII- stimulated rise in 12HETE production (10(-9)M AII, 160 +/- 4% of control; 10(-9) M AII plus 10(-7) M 5HETE, 90 +/- 1% of control production). However, 5HETE had no effect on the aldosterone response to potassium or ACTH, secretagogues that cause no activation of the 12LO pathway. These results suggest that the 5LO product 5HETE can selectively modulate AII-dependent aldosterone secretion. Further, the selective inhibitory effect of 5HETE on the AII effect in rat glomerulosa cells may be exerted by blockade of arachidonate metabolism via the 12LO pathway. These results suggest that the 5LO pathway may negatively modulate AII action in the adrenal zona glomerulosa.


This article has been cited by other articles:


Home page
EndocrinologyHome page
F. Liang, A. M. Kapoun, A. Lam, D. L. Damm, D. Quan, M. O'Connell, and A. A. Protter
B-Type Natriuretic Peptide Inhibited Angiotensin II-Stimulated Cholesterol Biosynthesis, Cholesterol Transfer, and Steroidogenesis in Primary Human Adrenocortical Cells
Endocrinology, August 1, 2007; 148(8): 3722 - 3729.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Hardy, F. Stanke-Labesque, M. Peoc'h, A. Hakim, P. Devillier, F. Caron, S. Morel, P. Faure, S. Halimi, and G. Bessard
Cysteinyl Leukotrienes Modulate Angiotensin II Constrictor Effects on Aortas From Streptozotocin-Induced Diabetic Rats
Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1751 - 1758.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Stanke-Labesque, P. Devillier, S. Veitl, F. Caron, J.-L. Cracowski, and G. Bessard
Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats
Cardiovasc Res, January 1, 2001; 49(1): 152 - 160.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. S. Kisch, A. Jaffe, E. Knoll, and N. Stern
Role of the Lipoxygenase Pathway in Angiotensin II–Induced Vasoconstriction in the Human Placenta
Hypertension, March 1, 1997; 29(3): 796 - 801.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society